1. In patients with ER-positive, HER2-negative advanced breast cancer who developed an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 ...
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in Lancet Oncology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer progression-free and overall survival than the placebo group. 2. ...
1. In patients with untreated metastatic or unresectable melanoma, the combination of Relatlimab and Nivolumab was associated with greater progression-free ...
